[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …
Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection …
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection …
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a …
X Liu, RH Shaw, ASV Stuart, M Greenland, PK Aley… - The Lancet, 2021 - thelancet.com
Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …
mass COVID-19 immunisation. However, we have previously reported that heterologous …
[HTML][HTML] Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a …
SAC Clemens, L Weckx, R Clemens, AVA Mendes… - The Lancet, 2022 - thelancet.com
Introduction The inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac, Sinovac) has
been widely used in a two-dose schedule. We assessed whether a third dose of the …
been widely used in a two-dose schedule. We assessed whether a third dose of the …
Reduced neutralisation of SARS-CoV-2 omicron B. 1.1. 529 variant by post-immunisation serum
W Dejnirattisai, RH Shaw, P Supasa, C Liu, ASV Stuart… - The Lancet, 2022 - thelancet.com
According to WHO, SARS-CoV-2 is estimated to have caused 265 million infections and
more than 5 million deaths over the past 2 years. Current vaccines are based on the original …
more than 5 million deaths over the past 2 years. Current vaccines are based on the original …
[HTML][HTML] Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in …
ASV Stuart, RH Shaw, X Liu, M Greenland, PK Aley… - The Lancet, 2022 - thelancet.com
Background Given the importance of flexible use of different COVID-19 vaccines within the
same schedule to facilitate rapid deployment, we studied mixed priming schedules …
same schedule to facilitate rapid deployment, we studied mixed priming schedules …
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
RH Shaw, A Stuart, M Greenland, X Liu, JSN Van-Tam… - The Lancet, 2021 - thelancet.com
There is significant international interest in heterologous prime-boost COVID-19 vaccination
to mitigate against supply shocks or shortages that might otherwise reduce the speed of …
to mitigate against supply shocks or shortages that might otherwise reduce the speed of …
[HTML][HTML] Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
More than 190 vaccines are currently in development to prevent infection by the novel
severe acute respiratory syndrome coronavirus 2. Animal studies suggest that while …
severe acute respiratory syndrome coronavirus 2. Animal studies suggest that while …
[HTML][HTML] A randomized trial of early endovenous ablation in venous ulceration
MS Gohel, F Heatley, X Liu, A Bradbury… - … England Journal of …, 2018 - Mass Medical Soc
Background Venous disease is the most common cause of leg ulceration. Although
compression therapy improves venous ulcer healing, it does not treat the underlying causes …
compression therapy improves venous ulcer healing, it does not treat the underlying causes …
[HTML][HTML] Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 …
Background Some high-income countries have deployed fourth doses of COVID-19
vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain …
vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain …
[HTML][HTML] Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine immunogenicity
varies between individuals, and immune responses correlate with vaccine efficacy. Using …
varies between individuals, and immune responses correlate with vaccine efficacy. Using …